Our results represent the discovery of first-in-class dual inhibitors of G9a/DNMTs and establish this chemical series as a promising therapeutic tool for unmet needs in haematological tumours. The gene discussed is EHMT2; the disease is hematopoietic and lymphoid cell neoplasm.